Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficacy and Safety Profile of Biphasic Insulin Aspart 30 (BIAsp 30) and Biphasic Human Insulin 30/70 (BHI 30/70) in Chinese Type 1 and 2 Diabetics

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.

Inclusion Criteria:

• Type 1 or 2 diabetes for at least 3 months
• Stabilised on current treatment with premixed human insulin for at least 4 weeks
• Body mass index (BMI) between 18-40 kg/m2
• HbA1c below 13.0%
• Able and willing to perform self-blood glucose monitoring

Exclusion Criteria:

• The receipt of any investigational drug within the last three months prior to this trial
• Has a history of drug abuse or alcohol dependence within the last 5 years
• Active proliferative retinopathy requiring laser or surgical intervention within the last year
• Recurrent major hypoglycaemia as judged by the Investigator
• Known or suspected allergy to trial product or related product